N-glycans of Human Protein C Inhibitor: Tissue-Specific Expression and Function by Sun, Wei et al.
N-glycans of Human Protein C Inhibitor: Tissue-Specific
Expression and Function
Wei Sun
1., Paola Grassi
2.,A ˚ke Engstro ¨m
1, Sanjeewani Sooriyaarachchi
3, Wimal Ubhayasekera
1, Julius
Hreinsson
4, Kjell Wa ˚nggren
4, Gary F. Clark
5, Anne Dell
2, Sophia Schedin-Weiss
1*
¤
1Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden, 2Division of Molecular Biosciences, Imperial College London, London,
United Kingdom, 3Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden, 4Department of Women’s and Children’s Health, Uppsala University
Hospital, Uppsala, Sweden, 5Department of Obstetrics, Gynecology and Women’s Health, University of Missouri, Columbia, Missouri, United States of America
Abstract
Protein C inhibitor (PCI) is a serpin type of serine protease inhibitor that is found in many tissues and fluids in human,
including blood plasma, seminal plasma and urine. This inhibitor displays an unusually broad protease specificity compared
with other serpins. Previous studies have shown that the N-glycan(s) and the NH2-terminus affect some blood-related
functions of PCI. In this study, we have for the first time determined the N-glycan profile of seminal plasma PCI, by mass
spectrometry. The N-glycan structures differed markedly compared with those of both blood-derived and urinary PCI,
providing evidence that the N-glycans of PCI are expressed in a tissue-specific manner. The most abundant structure (m/z
2592.9) had a composition of Fuc3Hex5HexNAc4, consistent with a core fucosylated bi-antennary glycan with terminal
Lewis
x. A major serine protease in semen, prostate specific antigen (PSA), was used to evaluate the effects of N-glycans and
the NH2-terminus on a PCI function related to the reproductive tract. Second-order rate constants for PSA inhibition by PCI
were 4.360.2 and 4.160.5 M
21s
21 for the natural full-length PCI and a form lacking six amino acids at the NH2-terminus,
respectively, whereas these constants were 4.860.1 and 2967M
21s
21 for the corresponding PNGase F-treated forms. The
7–8-fold higher rate constants obtained when both the N-glycans and the NH2-terminus had been removed suggest that
these structures jointly affect the rate of PSA inhibition, presumably by together hindering conformational changes of PCI
required to bind to the catalytic pocket of PSA.
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Introduction
Protein C inhibitor (PCI) is a 57 kD glycoprotein that belongs to
the serine protease inhibitor (Serpin) superfamily of proteins, and
exists in many tissues and fluids in humans, including reproductive
organs, semen, blood, urine, breast milk and skin [1,2]. PCI found
in blood originates from the liver and is capable of inhibiting
several serine proteases involved in the regulation of coagulation
and fibrinolysis, including activated protein C, thrombin, factor
Xa, various kallikreins and plasminogen activators. Additionally,
PCI has been found to have antimicrobial and antitumor
properties and thus appears to be a medically interesting versatile
protein [2].
PCI has been identified both in the human male and female
reproductive tracts. The concentration of PCI in follicular fluid is
similar to that in plasma [1,3]. In contrast, a 40-fold higher
concentration (3–4 mM) is present in the seminal plasma [1].
Seminal plasma PCI is mainly synthesized in seminal vesicles,
where it undergoes glycosylation and is subsequently secreted in an
active form. After ejaculation, it is inactivated by forming
complexes with prostate-specific antigen (PSA) [4,5,6], t-PA
(tissue-type plasminogen activator), u-PA (urokinase-type plasmin-
ogen activator) [7], and tissue kallikrein [8]. Although the function
of PCI in seminal plasma is not yet completely understood,
evidence showing that PCI plays a significant role in male fertility
has been published. PCI knock-out mice appear to be healthy but
males of this genotype are infertile due to abnormal spermato-
genesis as the Sertoli cell barrier is destroyed [9]. In a clinical
investigation, the inhibitory activities of PCI towards u-PA and t-
PA were absent in two infertile patients, suggesting that formation
of PCI complexes with u-PA and t-PA plays a role in fertilization
in the human [10]. Given that the physiological role of PSA is the
degradation of the major proteins of seminal coagula, Semeno-
gelin(Sg)-I and Sg-II, PCI also appears to be involved in the
regulation of semen liquefaction [11]. In addition, seminal plasma
PCI has been found to inhibit the binding and penetration of
human sperm to zona-free hamster oocytes [3,12]. The inhibitor
thus appears to be necessary for several steps in fertilization.
Plasma PCI has three N-glycosylation sites at Asn-230, Asn-243
and Asn-319 [13,14]. We and other groups have observed that the
N-glycans of PCI affect the rates of inhibition of several proteases
[14,15]. The primary structure of seminal PCI is identical to that
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29011of blood PCI [1]. The structures of the glycans attached to seminal
PCI have, however, not previously been reported. It is therefore
intriguing to investigate whether these glycans differ from those of
blood PCI and whether differences in glycosylation affect the
functions of PCI. Such information will be valuable for the future
potential use of recombinant PCI forms in medical treatments. In
this study, we have purified human seminal plasma PCI by
immunoaffinity chromatography and subsequently identified the
N-glycan structures by using matrix-assisted laser desorption
ionization time of flight mass spectrometry (MALDI-TOF MS),
which revealed marked differences compared with N-glycans from
blood and urinary PCI. The majority of the seminal plasma PCI
was either in an inactive, reactive-center-loop-(RCL)-cleaved form
or in complex with PSA and, thus, could not be used for protease
inhibition experiments. To investigate the effect of N-glycosylation
on PCI inhibition of a protease from the reproductive tract, we
therefore determined the PSA inhibition rates by active human
blood PCI before and after enzymatic removal of either all N-
linked glycans or the terminal sialic acids. These experiments were
performed for both full-length PCI and a variant lacking the 6-
amino-acid NH2-terminal peptide, previously found to constitute
,18% of blood plasma PCI [14]. The results revealed that the N-
glycans and the NH2-terminus together, but not alone, affect the
rate of PSA inhibition.
Results
Purification of seminal plasma PCI
Human seminal plasma PCI was purified by using three
consecutive chromatographic steps, two of which employed
monoclonal antibody columns against native or RCL-cleaved
PCI. In contrast to PCI from human blood [14], the majority of
seminal plasma PCI bound to the second column, recognizing
only RCL-cleaved PCI, indicating that most of the seminal plasma
is RCL-cleaved, either free or in complex with proteases.
SDS-PAGE and immunoblotting
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot of the purified seminal plasma PCI revealed two
broad bands, corresponding to molecular masses of 90–100 kDa
and 50–60 kDa (Fig. 1), in agreement with a previous study [1].
Peptide mapping by MS revealed that the 50–60 kDa band
contained cleaved PCI lacking 10 amino acids at the NH2-
terminus and 31 amino acids at the COOH-terminus, consistent
with the protein being both NH2-terminally cleaved and RCL-
cleaved (spectra not shown). The 90–100 kD band was found to
contain both PSA and cleaved PCI, verifying that a portion of PCI
in seminal plasma is in an SDS-stable complex with PSA, in
agreement with previous studies [1,4]. In order to obtain pure PCI
for N-glycan structure analysis, another gel chromatography step
was further employed to separate the free form of PCI from the
PCI-PSA complex.
MALDI-MS analysis of N-glycans released from PCI
Purified PCI from human seminal plasma was reduced/
carboxymethylated and tryptically digested to facilitate deglycosy-
lation with PNGase F. The released glycans were separated from
peptides and were analyzed by MALDI-MS after permethylation
and Sep-Pak purification (Fig. 2). The spectrum indicates that PCI
N-glycans have compositions consistent with mostly core-fucosy-
lated bi-antennary glycans, but some tri-antennary and tetra-
antennary glycans were also observed. The most abundant ion
(m/z 2592.9) has a composition (Fuc3Hex5HexNAc4) consistent
with a core fucosylated bi-antennary glycan with two terminal
Lewis
x. The second most abundant ion (m/z 2766.9) has a
composition (Fuc4Hex5HexNAc4) consistent with a core fucosy-
lated bi-antennary glycan with one terminal Lewis
x and one
terminal Lewis
y. Altogether, various combinations of Lewis
x,
Lewis
x/Lewis
x, Lewis
x/Lewis
y and Lewis
y/Lewis
y were observed
on the two–four antennae. The compositions of the peaks with five
or more fucose residues are consistent with core fucosylation
together with Lewis
x and Lewis
y epitopes on the three or four
antennae, as previously described by Pang et al [16]. The high
mannose content was very low and virtually no sialylation was
detected (Fig. 2 and Fig. S1).
Preparation of blood plasma PCI
PNGase F treated PCI was isolated using heparin-Sepharose
chromatography with an extended NaCl and pH gradient, as
described previously [14]. Desialylated PCI was isolated using ion
exchange chromatography and subsequently analyzed by native
PAGE (Fig. 3). Intact PCI migrated considerably further than the
desialylated PCI forms, verifying that the negatively charged sialic
acids had been efficiently removed by the neuraminidase
treatment. In addition, desialylated NH2-terminally cleaved PCI
(Fig. 3. Lane 2) migrated slightly further than desialylated full-
length PCI (Fig. 3. Lane 3).
Effects of PCI variants on PSA inhibition
Four PCI variants derived from human blood plasma were used
to determine the effects of N-glycans and the NH2-terminus on the
rates of PSA inhibition. The same variants were previously used
for studies of inhibition of factor Xa and thrombin [17]. The
stability of PSA was first evaluated over a 24-hour period in the
inhibition assay conditions used (Fig. 4A), verifying that the
enzyme retained 86% of the activity and is thus reasonably stable.
The effects of N-glycan removal and the 6 residue NH2-terminal
peptide of PCI on the rate of PSA inhibition were studied at 25uC.
PSA inhibition of intact and PNGase F-treated PCI fitted to a
monophasic single-exponential decay function (Fig. 4B). Similarly,
deglycosylated PCI with and without the NH2-terminus also fitted
to this type of function. A comparison of the second-order rate
constant for PSA inhibition by the four PCI variants is shown in
Fig. 5. These constants were 4.360.2 and 4.160.5 M
21s
21 for
full-length PCI and the variant lacking the six NH2-terminal
residues, respectively, showing that the rate of PSA inhibition was
not affected by removing the 6 NH2-terminal residues. Moreover,
second-order rate constants were 4.860.1 and 2967M
21s
21 for
the PNGase F-treated full length and NH2-terminal-free PCI,
Figure 1. Western blot and SDS-PAGE image of purified PCI.
Human seminal and blood plasma PCI were purified as described in
Materials and Methods. Products were analyzed by SDS-PAGE, followed
by staining with Coomassie Brilliant Blue R-250 or subjected to western
blot. Lane 1, western blot analysis of blood plasma PCI; Lane 2, western
blot analysis of seminal plasma PCI; Lane 3, SDS-PAGE of seminal
plasma PCI.
doi:10.1371/journal.pone.0029011.g001
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affected by the removal of N-glycans alone, whereas the combined
loss of N-glycans and the NH2-terminal 6-residue peptide resulted
in a 7–8 fold increase in the rate of PSA inhibition. One major
difference between the N-glycans of PCI from blood and seminal
plasma was the absence (seminal PCI) or presence (blood PCI) of
negatively charged sialic acids. To investigate whether the joint
effect of the N-glycans and the NH2-terminus on PSA inhibition
was affected by the sialic acids, we therefore also determined the
effects of neuraminidase treatment of blood PCI on the rates of
PCI inhibition of PSA. Second-order rate constants were 5.260.7
and 5.860.6 M
21s
21 for the neuraminic acid free, full length and
neuraminic acid free, NH2-ternimally cleaved PCI, demonstrating
that sialylation of PCI does not have any major effect on the rate of
PSA inhibition. All the rate constants are expressed as the mean 6
SD of two independent experiments, each based on 4–6 time
points.
Modeling of the PCI-PSA interaction
Because there are no crystal structures available for the PCI-
PSA complex or the NH2-terminus of PCI, we created models of
these structures. The displayed conformation of the RCL loop of
PCI, as present in the human PCI crystal structure (PDB entry
2OL2), does not fit well into the catalytic pocket of PSA. We
therefore show the two molecules individually (Fig. 6). Adjustments
Figure 2. MALDI-TOF mass spectrum of permethylated PCI N-glycans from human seminal plasma. N-glycans were derived from 50% (v/
v) acetonitrile fraction from a C18 Sep-Pak. All molecular ions are [M+Na]
+, and nomial masses of the
12C isotope are shown. Putative structures based
on composition and knowledge of biosynthetic pathways are shown. The symbols for the monosaccharide units are explained in the picture.
doi:10.1371/journal.pone.0029011.g002
Figure 3. Native PAGE of desialylated blood plasma PCI. PCI was
desialylated,,purified and analyzed by native PAGE, as described in
Materials and Methods. The gel was stained with Ruby protein stain.
Lane 1, native PCI; Lane 2, desialylated N-terminally cleaved PCI; Lane 3,
desialylated full-length PCI.
doi:10.1371/journal.pone.0029011.g003
N-glycans of Human Protein C Inhibitor
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29011are consequently required for optimal complex formation. The
suggested conformational change is supported by the flexibility of
the RCL loop observed in related crystals structures [18,19].
Discussion
Due to the versatility of PCI, the mechanisms of regulation of its
various functions are intriguing to investigate. Previous studies
have shown that post-translational modifications of the inhibitor,
i.e. glycosylation and protease processing, affect the specificity of
PCI for proteases [14,15,20]. However, many clues about the
structure/function of the covalently linked glycans, as well as the
segments of the inhibitor that are proteolytically released, remain
unknown. Herein, we show for the first time the structural profile
of N-glycans of human seminal plasma PCI, determined by mass
spectrometric methods. Moreover, we report the effects of the N-
glycans and the NH2-terminus on the rate of inhibition of PSA, a
major serine protease in seminal plasma. Since the seminal plasma
glycoforms of PCI are inactive, we used the four PCI variants
derived from blood that were previously employed to study
kinetics for factor Xa and thrombin inhibition. Testing of these
variants allowed us to observe different effects of the N-glycans and
the NH2-terminus on the three proteases.
Our group previously reported that blood plasma PCI is micro-
heterogeneous, which was revealed by the appearance of at least
six clear bands in SDS-PAGE [14]. The various PCI sizes were
found to be caused by differences in N-glycan structures, N-glycan
occupancy and the presence of two forms that differ by the
presence or absence of six amino acids at the NH2-terminus. All
three potential N-glycosylation sites were occupied in the majority
of PCI, although a small fraction of the PCI sample lacked the
glycan at Asn-243 [14]. In contrast, the SDS-PAGE of seminal
plasma PCI reported here does not show any clear separation of
PCI variants, although the broad appearance of the band in the
gel indicates that there are several variants that are not as well
separated. This difference in appearance on SDS-PAGE of blood
PCI compared to seminal plasma PCI is presumably explained by
the differences in posttranslational modifications. For instance, all
seminal plasma PCI lacked an NH2-terminally cleaved peptide,
although this peptide was ten residues (HRHHPREMKK) instead
of six. This ten-residue NH2-terminal peptide is highly positively
charged and thus likely affects the functional properties of PCI.
The N-glycans of seminal plasma PCI consist mainly of core-
fucosylated, biantennary lewis
X and/or lewis
Y-capped structures.
They are completely devoid of sialic acids, and therefore differ
markedly in sequence from those previously identified in blood
PCI [14]. Our previous study showed that the N-glycans from
blood PCI consist of bi-, tri, and tetra-antennary structures of
which the most abundant structure is a non-fucosylated bi-
antennary glycan with both antennae capped with sialic acid [14].
A small fraction of the blood PCI N-glycans carried sialyl-Lewis
X
epitopes. The N-glycans linked to urinary PCI consist of mainly
core fucosylated, biantennary structures that are to a great extent
Figure 4. Rate of PSA inhibition by full-length native PCI derived from blood. The inhibition of PSA was measured as a function of time by
a discontinuous assay, as described in Materials and Methods.
doi:10.1371/journal.pone.0029011.g004
Figure 5. Effects of N-glycans and the D6-N-terminus on the
rate of PCI inhibition of PSA. The inhibition of PSA by untreated full-
length, untreated D6-N-cleaved, deglycosylated full-length, deglycosy-
lated D6-N-cleaved, desialylated full-length and desialylated D6-N-
cleaved PCI isolated from blood plasma were measured as a function of
time by a discontinuous assay. The resulting second-order rate
constants are displayed. Data are the mean 6 SD of two independent
experiments, each based on 4–6 time points.
doi:10.1371/journal.pone.0029011.g005
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of the urinary PCI glycans have antennae composed of lacdiNAc
(Gal NAcb1-4GlcNAc), a rarer sequence that has been observed in
neither blood nor seminal plasma PCI N-glycans. The source of
urinary PCI has not been completely identified so far. However,
Radtke et al. have shown that PCI is synthesized in tubular cells of
the kidney, suggesting that the kidney is a source for urinary PCI
[21]. The differences observed in N-glycan structures of PCI in
seminal plasma, urine and blood supports this conclusion and
demonstrates that the N-glycosylation of PCI displays a highly
tissue-specific expression (Fig. 7).
A recent study revealed the overall seminal plasma N-glycome,
which consists of bi-, tri- and tetraantennary sequences [16], of
which several contain lewis
X and/or lewis
Y-capped structures. In
contrast to the N-glycans of seminal plasma PCI, the seminal
plasma N-glycome also contains a substantial portion of high-
mannose as well as sialylated structures. Moreover, sialylated
glycans are abundant in seminal plasma from some individuals
and minor in others according to this glycomics analysis, while
they appear to be totally absent in PCI. Our results thus
demonstrate that PCI neither contributes to the individual
differences in sialylated N-glycans nor to the high-mannose
structures observed in the seminal plasma glycome.
The highest concentration of PCI in human is found in seminal
plasma. Although the exact physiological role of PCI in semen is
still not clear, we have reason to believe that PSA is a major target
protease for PCI inactivation in the semen, because PSA occurs at
a concentration of 15–60 mM, is the most abundant serine
protease in seminal fluid [22] and about 34–44% of the total
PCI in semen is in complex with PSA [4,5]. Even so, rate constants
for the inhibition of PSA by PCI have not previously been
documented. Since all purified seminal plasma PCI was in the
proteolytically modified and inactive state, blood plasma PCI was
used to determine the PSA inhibition rates. The second-order rate
constant (k2) for PSA inhibition by native full-length PCI and PCI
lacking the 6-residue NH2-terminal peptide were not statistically
different (4.360.2 and 4.160.5 M
21s
21, respectively). This
finding indicated that the six NH2-terminal residues do not
contribute to the PSA inhibition rates. The same rates are
2.7610
3 M
21s
21, ,1610
3 M
21s
21, 2.4610
5 M
21s
21 for PCI
inhibition of t-PA, u-PA and acrosin, respectively [14,23,24,25].
The rate for PSA inhibition by PCI is thus very low compared to
Figure 6. Modeling of the NH2-terminal parts of PCI and the PCI-PSA complex. (A) Ribbon cartoon of PCI (PDB entry 2OL2) with the fantasy
model of the NH2-terminal part. Residues 1–6 (HRHHPR), 7–10 (EMKK) and 11–28 (R11 – D28) of the fantasy model are shown in cyan, orange and
black respectively. N-glycan-attaching residues and the RCL loop, which interact with PSA in the PCI-PSA complex, are shown in blue and brick red,
respectively. Amino- and carboxy-termini are labeled NH2 and COOH, respectively, where the surface of PCI is shown in light grey. (B) Stereo
illustration of the surface of PSA, displaying the catalytic pocket forming loops in orange. The catalytic residues are marked in red. The RCL loop of PCI
binds to this catalytic pocket.
doi:10.1371/journal.pone.0029011.g006
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proportion of PCI in seminal plasma forms a complex with PSA.
Similar observations have been reported previously and are
presumably due to the high concentration of PSA in semen [2,5].
Moreover, N-glycans alone did not significantly contribute to the
k2 for PCI inhibition of PSA. However, the combined loss of N-
glycans and the D6-NH2-terminus significantly enhanced the
reaction, indicating that these structures together contribute to the
slow PSA-PCI reaction velocity. These results may be explained
by the possibility that N-linked glycans and the NH2-terminus
together sterically hinder a conformational change required for the
RCL loop of PCI to fit into the catalytic pocket of PSA. This
explanation is reasonable considering that for serpin-protease
inhibition reactions it has been proposed that the first step, i.e. the
formation of the encountering complex, is rate limiting [26]. Since
the terminal neuraminic acid on PCI did not have any major effect
on PSA inhibition rates, we further concluded that the shedding
caused by the N-glycans and the NH2-terminus together is not
affected by the charge of the N-glycans. It will be highly interesting
in future investigations to determine the effects of the seminal
plasma-specific posttranslational modifications on PCI functions,
such as the inhibition of various proteases and cell-surface receptor
interactions. However, protease inhibition experiments will
require the isolation of active seminal plasma-derived PCI, which
has proven to be very difficult to achieve, due to the high
concentrations of serine proteases in seminal plasma. Alternatively,
it may be possible to produce recombinant PCI expressing the
seminal plasma PCI N-glycans, although this is a difficult task
because it requires the precise expression of the correct
glycosyltransferases.
A recent study indicates that PCI could also play another
functional role in the human male and female reproductive
systems. The immune lectin designated DC-SIGN (dendritic cell-
specific intercellular adhesion molecule-3-nonintegrin) is associat-
ed with both mature and immature dendritic cells (DCs) [27,28].
Many human pathogens bind to DC-SIGN, enabling their
detection, uptake and the development of specific adaptive
immune responses by DCs [29]. However, DC-SIGN also binds
to several endogenous glycoproteins, and such interactions are
currently thought to promote immune homeostasis [28]. Many
proteins are specifically produced in the male urogenital tract after
the onset of puberty, but they have not been subjected to thymic
education. Such autoantigens could trigger immune responses in
both the human male and female reproductive systems [30].
However, PCI and three other glycoproteins (clusterin, galectin-3
binding protein, and prostatic acid phosphatase) have recently
been defined as endogenous glycoprotein ligands for DC-SIGN in
seminal plasma [31]. Extensive fucosylation was important for
these interactions. Therefore seminal plasma PCI could also have
an immunomodulatory effect in both the male and female
reproductive tracts, in which fucosylation plays a critical role.
The results presented here provide further support that
posttranslational modifications affect the functional specificity of
PCI, which is medically relevant because PCI can act for instance
as an anti-inflammatory and antitumor agent. It is also essential for
all stages of reproduction. Therefore it may be used for therapeutic
purposes. It was previously shown that the overall removal of N-
linked glycans and the NH2-terminal peptide of PCI affect the
inhibition rates in the presence but not in the absence of the
cofactors heparin and thrombomodulin [14]. For factor Xa, the
NH2-terminal peptide of PCI was found to affect the inhibition
rates both in the absence and the presence of heparin [14]. PSA, in
contrast, is unique in that only the combination of the N-glycans
and the NH2-terminus of PCI affect the rate of its inhibition.
Materials and Methods
Seminal plasma PCI purification
This study had been approved by the Regional Ethical Review
Board committee in Uppsala, at Uppsala University and at the
Uppsala Univerity Hospital. We obtained informed written
consent from all participants involved in the study. Human
semen, obtained from several healthy donors (according to World
Health Organization guidelines), were allowed to liquefy and then
centrifuged at 500–1000 g for 10 min. The supernatant was
collected and then mixed with 10 mM (final concentration)
benzamidine chloride (Sigma-Aldrich, St. Louis, US). Seminal
plasma was then stored at 220 uC and the samples from several
individuals were pooled before use. Purification of PCI was carried
out as described before [14] with only minor changes. Briefly,
three consecutive affinity chromatography steps were employed,
with the use of two immobilized monoclonal antibodies and one
heparin-Sepharose chromatography step. The first immobilized
antibody recognizes all forms of PCI, whereas the second antibody
recognizes only RCL-cleaved and complexed forms of PCI. To
separate the free seminal PCI from its complex forms, an
additional gel chromatographic step, using a Superdex 75 column
(GE healthcare, Uppsala, Sweden), was employed. Protein was
then concentrated by filter centrifugation using Amicon Ultra-4
centrifugal filter devices (Millipore Corp., Bedford, MA). Protein
concentration was determined by UV absorbance with the use of
the extinction coefficient determined previously at 280 nm
(31300 M
21cm
21) [32].
SDS-PAGE and immunoblotting
The purified protein samples were analyzed by SDS-PAGE in
10% gels with the Laemmli [33] system. Gels were then subjected
to Coomassie Brilliant Blue R-250 staining or immunodetection.
For western blot, protein bands were transferred onto a
nitrocellulose sheet (Schleicher & Schuell BioScience, Dassel,
Germany). A primary antibody, rabbit anti-human PCI (Abcam,
Cambridge, UK) and a HRP (horseradish peroxidase) conjugated
Figure 7. Tissue-specific expression of N-glycans on PCI. Major
N-glycans of PCI derived from blood plasma, seminal plasma and urine
are framed in light red, blue and yellow, respectively. N-glycan structure
of urinary PCI is drawn according to [13]. * represents the most
abundant glycan. Glycan marked with ‘‘S’’ has a special lacdiNAc
(GalNAcb1-4GlcNAc) structure (constitutes about 12% of the total N-
glycans in urinary PCI [13]). This structure has not been observed in
blood or seminal plasma PCI N-glycans.
doi:10.1371/journal.pone.0029011.g007
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were used. The signal was developed using ECL plus reagents (GE
healthcare, Uppsala, Sweden) and the membrane was then
exposed to Fuji film.
Bands were excised from the Coomassie stained SDS-PAGE
gel; then subjected to MS analysis for peptide mapping, as
described previously [14].
MS analysis for N-glycan structure determination
Purified PCI was reduced in 600 mM Tris-HCl buffer, pH 8.4,
containing 2 mg/ml dithiothreitol (37uC for 45 min), and
carboxymethylated by addition of 12 mg/ml iodoacetic acid
(room temperature for 1.5 h). Carboxymethylation was termi-
nated by dialysis against 50 mM NH4HCO3,p H8 . 5 ,a t4 uCf o r
48 h, followed by lyophilisation. PCI was incubated with trypsin
(Sigma) at a 50:1 ratio (w/w) in 50 mM NH4HCO3,p H8 . 4 ,f o r
16 h at 37uC. The digestion was terminated by heating at 100uC
for 3 min, followed by C18 Sep-Pak chromatography (Waters
Corp.). Bound peptides were eluted with either 20% (v/v) or 40%
(v/v) propanol in 5% aqueous acetic acid, pooled and lyophilised.
PNGase F (Roche) digestion was carried out in 50 mM
ammonium bicarbonate, pH 8.5, for 16 h at 37uC with 3 Roche
U of enzyme. The released N-glycans were separated from
peptides by Sep-Pak C18 (Waters Corp.) as described [34].
Permethylation of glycans was performed using the sodium
hydroxide procedure [34]. MALDI-TOF data were acquired on
a Voyager-DE sSTR mass spectrometer (PerSeptive Biosystems,
Framingham, MA, USA) in the reflectron mode with delayed
extraction. Permethylated samples were dissolved in 10 mlo f
methanol in water, and 1 ml of dissolved sample was pre-mixed
with 1 ml of matrix (10 mg/ml 2,5-dihydroxybenzoic acid (DHB)
in 80% (v/v) aqueous methanol) before loading onto a metal
plate.
Preparation of blood plasma PCI
Blood plasma PCI used for kinetic studies was purified as
described previously [14]. To obtain N-glycan free PCI, the
native protein was treated with PNGase F, as described
previously [14]. The native and the N-glycan-free PCI forms
were further subjected to an extended heparin sepharose
gradient as described previously, to separate full-length PCI
from the form lacking a 6-residue NH2-terminal peptide [14].
Neuraminic acid-free PCI was prepared by incubating 300 mg
PCI with 15000 NEB U neuraminidase (New England BioLabs)
in 20 mM Tris-HCl, 0.1 M NaCl, pH 7.4 at 37 uCf o r3h o u r s .
This Neuraminidase catalyzes the hydrolysis of a2–3, a2–6, and
a2–8 linked N-acetyl-neuraminic acid residues from glycopro-
teins and oligosaccharides. Ion exchange chromatography on a
mono Q 5/50 GL column (GE Healthcare, Uppsala, Sweden)
was used to separate full-length PCI from NH2-terminally
cleaved PCI. A gradient was employed with running buffers A
and B containing 0.1 and 1 M NaCl, respectively, in 20 mM
sodium phosphate, 0.1 mM EDTA and pH 7.4. The gradient
w a ss e g m e n t e da sf o l l o w s :0m i n ,0 %B ;6 0m i n ,4 0 %B ;6 5m i n ,
1 0 0 %B ;6 7 m i n ,0 %B ;7 2 m i n ,0 %B .T h ef l o w - r a t ew a s
0.5 ml/min. The resulting peaks were collected and concentrat-
ed, and the buffer was exchanged into 20 mM Tris-HCl, 0.1 M
N a C l ,p H7 . 4 ,w i t hA m i c o nU l t r a - 4c e n t r i f u g a lf i l t e rd e v i c e s
(Millipore Corp.). The protein fractions were then analyzed by
7.5% native PAGE.
Kinetics of PSA inhibition
Second-order rate constants for the inhibition of PSA by the
PCI variants were measured under pseudo-first-order condi-
tions, using a discontinuous assay [35] in 20 mM Tris-HCl,
0.1 M NaCl and pH 7.4 at 25uC. PSA (final concentration
350 nM) was incubated with a 10-fold excess of PCI. After
different reaction times, varying from 30 min to 24 hours,
aliquots were diluted in the assay buffer containing 400 mM
chromogenic substrate Meo-Suc-Arg-Pro-Tyr-pNA (Calbio-
chem, Darmstadt, Germany) in the final system. The initial
rates of the residual PSA activity were monitored in a Tecan
Infinite M200 96-well plate reader at 405 nm and plotted
against the incubation times. Observed pseudo first-order rate
constants, kobs, were obtained by nonlinear least-squares fitting
of such plots to a single-exponential decay function based on
4–6 time points [35]. Second-order rate constants were
calculated by dividing kobs by the active PCI concentration
[35].
To ensure that the loss of PSA activity over time in the PCI
inhibition assay was caused by PCI inhibition, the stability of PSA
over time was determined under the same conditions as described
above. PSA (350 nM) was incubated in the assay buffer at 25 uC.
At different time intervals, from 2 to 24 hours, aliquots were
drawn from the incubation, and the residual protease activity was
measured.
Modeling of PCI and PSA
A fantasy model of the NH2-terminus (from residues His1-
Asp28) of PCI was modeled using crystal structures similar to
PCI. The PDB entry 2OL2 [36] was the starting model to build
the additional residues in the crystallographic program O. PSI-
BLAST searches [37] located the similar structures in the protein
data bank (PDB) [38]. The structures were superimposed by the
program LSQMAN [39] and inspected in O. The modeling of
the PCI-PSA complex was accomplished by replacing the
molecules of alaserpin and anionic trypsin II complex structure
(PDB entry 1K9O) [40] with those of PCI (sequence identity
24%) and PSA (PDB entry 2ZCH, sequence identity 42%) [41],
respectively. Figure 6 was prepared using PyMOL (http://www.
pymol.org/).
Supporting Information
Figure S1 Predicted sialylated structures. Cartoon repre-
sentations of predicted sialylated structures are shown in the
bottom panel. Structures are based on a previous study on human
seminal plasma by Pang et al. (reference 16). The upper panel
shows a zoomed view of human seminal plasma PCI MALDI-
TOF spectrum. The light blue arrows indicate the expected m/z
values of predicted sialylated structures. No peak corresponding to
the expected m/z values have been observed above the
background noise.
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